Neuro-oncology Overview

Principles

Definition

Neuro-oncology is an interdisciplinary academic and clinical field dedicated to the study, diagnosis, and treatment of primary and metastatic neoplasms affecting the central and peripheral nervous systems. It encompasses research into the molecular biology, pathology, and clinical behaviour of these tumors, alongside the development and application of therapeutic modalities aimed at improving patient outcomes and quality of life.

Ontological type

Therapeutic Modalities

Core Tumor Types

Diagnostic Techniques

Key developments

Key Figures

Foundational Chemoradiation Era era

Charles B. Wilson[1] was a leading neuro-oncologist in the Foundational Chemoradiation Era, with affiliations at University of California, San Francisco[3] and Baylor College of Medicine[4]. His work helped shape radiotherapy-centered multimodal management through trials such as Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas[7], Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after Surgery[8], and Cell kinetic analyses of human malignant brain tumors (gliomas)[9], which were important for understanding treatment sequencing, efficacy, and tumor biology in that era. M. S. Mahaley[2] was another pivotal figure in the era, with key work associated with University of Pittsburgh[5] and Duke University[6]. His contributions are exemplified by the 1978 Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas[7], which helped establish evidence for combining nitrosourea chemotherapy with radiotherapy and guided subsequent multimodal protocols.

Molecular Classification Era era

Roger Stupp [1], affiliated with Johns Hopkins University [3] and the University of California, Los Angeles [4], emerged as a leading figure in the Molecular Classification Era. His key contributions include Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma [7], which established a standard of care; the demonstration of MGMT promoter methylation as a predictive biomarker in glioblastoma treated with temozolomide [8], and the Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial [9], which refined risk stratification and guided treatment decisions in this era. Martin J. van den Bent [2], with Radboud University Nijmegen [5] and Heidelberg University [6], co-led pivotal work in consolidating molecular approaches in glioblastoma trials, notably Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma [7] and Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis [9], shaping trial design and prognosis-based stratification. Martin J. van den Bent [2], building on affiliations at Radboud University Nijmegen [5] and Heidelberg University [6], contributed to centralized neuropathology and biomarker-driven risk stratification that underpinned standardized endpoints in trials of this era.

Integrated Molecular Immuno-Oncology era

Carol Kruchko [1] is associated with the Institute of Cancer Research [3] and the University of California, San Francisco [4] during this era. Her key contributions include the CBTRUS Statistical Reports documenting incidence in 2006-2010 [5], 2010-2014 [7], and 2012-2016 [6], which provided essential epidemiologic baselines that informed biomarker-driven trial design and resource planning in integrated molecular immuno-oncology. Jill S. Barnholtz-Sloan [2] is linked with the Institute of Cancer Research [3] and the University of California, San Francisco [4] in this era. Her work on these CBTRUS Statistical Reports (2006-2010 [5], 2010-2014 [7], 2012-2016 [6]) established nationwide epidemiologic benchmarks and underpinned biomarker-driven trial planning and health-system guidance in integrated neuro-oncology.